Morphle Labs is a deeptech pathology company headquartered in Bengaluru, India, with U.S. operations, building an end-to-end automated digital pathology stack. Its core products include RoboTome, a robotic system that automates tissue sectioning, and MorphoLens, a high-throughput whole-slide scanning system, combined with AI to digitize and analyze pathology slides for cancer diagnosis. By automating the labor-intensive steps of slide preparation and scanning, Morphle aims to make digital pathology faster, more consistent, and more accessible to labs that lack large specialist staffs, addressing a global shortage of pathologists. In November 2025 the company raised a $5M Series A led by Inflexor Ventures, with the capital earmarked for scaling manufacturing of its RoboTome and MorphoLens hardware and expanding deployments.